|
1
|
Al Rabadi L and Bergan R: A way forward
for cancer chemoprevention: Think local. Cancer Prev Res (Phila).
10:14–35. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Port ER, Montgomery LL, Heerdt AS and
Borgen PI: Patient reluctance toward tamoxifen use for breast
cancer primary prevention. Ann Surg Oncol. 8:580–585. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ropka ME, Keim J and Philbrick JT: Patient
decisions about breast cancer chemoprevention: A systematic review
and meta-analysis. J Clin Oncol. 28:3090–3095. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Aggarwal BB, Kunnumakkara AB, Harikumar
KB, Gupta SR, Tharakan ST, Koca C, Dey S and Sung B: Signal
transducer and activator of transcription-3, inflammation, and
cancer: How intimate is the relationship? Ann N Y Acad Sci.
1171:59–76. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Leslie K, Lang C, Devgan G, Azare J,
Berishaj M, Gerald W, Kim YB, Paz K, Darnell JE, Albanese C, et al:
Cyclin D1 is transcriptionally regulated by and required for
transformation by activated signal transducer and activator of
transcription 3. Cancer Res. 66:2544–2552. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bowman T, Broome MA, Sinibaldi D, Wharton
W, Pledger WJ, Sedivy JM, Irby R, Yeatman T, Courtneidge SA and
Jove R: Stat3-mediated Myc expression is required for Src
transformation and PDGF-induced mitogenesis. Proc Natl Acad Sci
USA. 98:7319–7324. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bromberg JF, Wrzeszczynska MH, Devgan G,
Zhao Y, Pestell RG, Albanese C and Darnell JE Jr: Stat3 as an
oncogene. Cell. 98:295–303. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gritsko T, Williams A, Turkson J, Kaneko
S, Bowman T, Huang M, Nam S, Eweis I, Diaz N, Sullivan D, et al:
Persistent activation of stat3 signaling induces survivin gene
expression and confers resistance to apoptosis in human breast
cancer cells. Clin Cancer Res. 12:11–19. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tsareva SA, Moriggl R, Corvinus FM,
Wiederanders B, Schütz A, Kovacic B and Friedrich K: Signal
transducer and activator of transcription 3 activation promotes
invasive growth of colon carcinomas through matrix
metalloproteinase induction. Neoplasia. 9:279–291. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Niu G, Wright KL, Huang M, Song L, Haura
E, Turkson J, Zhang S, Wang T, Sinibaldi D, Coppola D, et al:
Constitutive Stat3 activity up-regulates VEGF expression and tumor
angiogenesis. Oncogene. 21:2000–2008. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Niu G, Briggs J, Deng J, Ma Y, Lee H,
Kortylewski M, Kujawski M, Kay H, Cress WD, Jove R and Yu H: Signal
transducer and activator of transcription 3 is required for
hypoxia-inducible factor-1alpha RNA expression in both tumor cells
and tumor-associated myeloid cells. Mol Cancer Res. 6:1099–1105.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kinjyo I, Inoue H, Hamano S, Fukuyama S,
Yoshimura T, Koga K, Takaki H, Himeno K, Takaesu G, Kobayashi T and
Yoshimura A: Loss of SOCS3 in T helper cells resulted in reduced
immune responses and hyperproduction of interleukin 10 and
transforming growth factor-beta 1. J Exp Med. 203:1021–1031. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Garcia R, Yu CL, Hudnall A, Catlett R,
Nelson KL, Smithgall T, Fujita DJ, Ethier SP and Jove R:
Constitutive activation of Stat3 in fibroblasts transformed by
diverse oncoproteins and in breast carcinoma cells. Cell Growth
Differ. 8:1267–1276. 1997.PubMed/NCBI
|
|
14
|
Huang M, Page C, Reynolds RK and Lin J:
Constitutive activation of stat 3 oncogene product in human ovarian
carcinoma cells. Gynecol Oncol. 79:67–73. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Mora LB, Buettner R, Seigne J, Diaz J,
Ahmad N, Garcia R, Bowman T, Falcone R, Fairclough R, Cantor A, et
al: Constitutive activation of Stat3 in human prostate tumors and
cell lines: Direct inhibition of Stat3 signaling induces apoptosis
of prostate cancer cells. Cancer Res. 62:6659–6666. 2002.PubMed/NCBI
|
|
16
|
Corvinus FM, Orth C, Moriggl R, Tsareva
SA, Wagner S, Pfitzner EB, Baus D, Kaufmann R, Huber LA, Zatloukal
K, et al: Persistent STAT3 activation in colon cancer is associated
with enhanced cell proliferation and tumor growth. Neoplasia.
7:545–555. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Guo C, Yang G, Khun K, Kong X, Levy D, Lee
P and Melamed J: Activation of Stat3 in renal tumors. Am J Transl
Res. 1:283–290. 2009.PubMed/NCBI
|
|
18
|
Schaefer LK, Ren Z, Fuller GN and Schaefer
TS: Constitutive activation of Stat3alpha in brain tumors:
Localization to tumor endothelial cells and activation by the
endothelial tyrosine kinase receptor (VEGFR-2). Oncogene.
21:2058–2065. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wei D, Le X, Zheng L, Wang L, Frey JA, Gao
AC, Peng Z, Huang S, Xiong HQ, Abbruzzese JL and Xie K: Stat3
activation regulates the expression of vascular endothelial growth
factor and human pancreatic cancer angiogenesis and metastasis.
Oncogene. 22:319–329. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chan KS, Sano S, Kataoka K, Abel E,
Carbajal S, Beltran L, Clifford J, Peavey M, Shen J and Digiovanni
J: Forced expression of a constitutively active form of Stat3 in
mouse epidermis enhances malignant progression of skin tumors
induced by two-stage carcinogenesis. Oncogene. 27:1087–1094. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Blando JM, Carbajal S, Abel E, Beltran L,
Conti C, Fischer S and DiGiovanni J: Cooperation between Stat3 and
Akt signaling leads to prostate tumor development in transgenic
mice. Neoplasia. 13:254–265. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kataoka K, Kim DJ, Carbajal S, Clifford JL
and DiGiovanni J: Stage-specific disruption of Stat3 demonstrates a
direct requirement during both the initiation and promotion stages
of mouse skin tumorigenesis. Carcinogenesis. 29:1108–1114. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
De Andrea M, Ritta M, Landini MM, Borgogna
C, Mondini M, Kern F, Ehrenreiter K, Baccarini M, Marcuzzi GP,
Smola S, et al: Keratinocyte-specific stat3 heterozygosity impairs
development of skin tumors in human papillomavirus 8 transgenic
mice. Cancer Res. 70:7938–7948. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Banerjee K and Resat H: Constitutive
activation of STAT3 in breast cancer cells: A review. Int J Cancer.
138:2570–2578. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ishii Y, Waxman S and Germain D: Tamoxifen
stimulates the growth of cyclin D1-overexpressing breast cancer
cells by promoting the activation of signal transducer and
activator of transcription 3. Cancer Res. 68:852–860. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Marotta LL, Almendro V, Marusyk A,
Shipitsin M, Schemme J, Walker SR, Bloushtain-Qimron N, Kim JJ,
Choudhury SA, Maruyama R, et al: The JAK2/STAT3 signaling pathway
is required for growth of CD44(+)CD24(−) stem cell-like breast
cancer cells in human tumors. J Clin Invest. 121:2723–2735. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Siddiquee K, Zhang S, Guida WC, Blaskovich
MA, Greedy B, Lawrence HR, Yip ML, Jove R, McLaughlin MM, Lawrence
NJ, et al: Selective chemical probe inhibitor of Stat3, identified
through structure-based virtual screening, induces antitumor
activity. Proc Natl Acad Sci USA. 104:7391–7396. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lin L, Amin R, Gallicano GI, Glasgow E,
Jogunoori W, Jessup JM, Zasloff M, Marshall JL, Shetty K, Johnson
L, et al: The STAT3 inhibitor NSC 74859 is effective in
hepatocellular cancers with disrupted TGF-beta signaling. Oncogene.
28:961–972. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chen W, Shen X, Xia X, Xu G, Ma T, Bai X
and Liang T: NSC 74859-mediated inhibition of STAT3 enhances the
anti-proliferative activity of cetuximab in hepatocellular
carcinoma. Liver Int. 32:70–77. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Muller WJ, Sinn E, Pattengale PK, Wallace
R and Leder P: Single-step induction of mammary adenocarcinoma in
transgenic mice bearing the activated c-neu oncogene. Cell.
54:105–115. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Bouchard L, Lamarre L, Tremblay PJ and
Jolicoeur P: Stochastic appearance of mammary tumors in transgenic
mice carrying the MMTV/c-neu oncogene. Cell. 57:931–936. 1989.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Guy CT, Cardiff RD and Muller WJ:
Activated neu induces rapid tumor progression. J Biol Chem.
271:7673–7678. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Huggins C, Morii S and Grand LC: Mammary
cancer induced by a single dose of polynuclear hydrocarbons: Routes
of administration. Ann Surg. 154 (Suppl 6):S315–S318. 1961.
View Article : Google Scholar
|
|
34
|
Ariga R, Zarif A, Korasick J, Reddy V,
Siziopikou K and Gattuso P: Correlation of her-2/neu gene
amplification with other prognostic and predictive factors in
female breast carcinoma. Breast J. 11:278–280. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Dowsett M, Allred C, Knox J, Quinn E,
Salter J, Wale C, Cuzick J, Houghton J, Williams N, Mallon E, et
al: Relationship between quantitative estrogen and progesterone
receptor expression and human epidermal growth factor receptor 2
(HER-2) status with recurrence in the arimidex, tamoxifen, alone or
in combination trial. J Clin Oncol. 26:1059–1065. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Konecny G, Pauletti G, Pegram M, Untch M,
Dandekar S, Aguilar Z, Wilson C, Rong HM, Bauerfeind I, Felber M,
et al: Quantitative association between HER-2/neu and steroid
hormone receptors in hormone receptor-positive primary breast
cancer. J Natl Cancer Inst. 95:142–153. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Bartkova J, Barnes DM, Millis RR and
Gullick WJ: Immunohistochemical demonstration of c-erbB-2 protein
in mammary ductal carcinoma in situ. Hum Pathol. 21:1164–1167.
1990. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Lodato RF, Maguire HC Jr, Greene MI,
Weiner DB and LiVolsi VA: Immunohistochemical evaluation of
c-erbB-2 oncogene expression in ductal carcinoma in situ and
atypical ductal hyperplasia of the breast. Mod Pathol. 3:449–454.
1990.PubMed/NCBI
|
|
39
|
Lu C, Speers C, Zhang Y, Xu X, Hill J,
Steinbis E, Celestino J, Shen Q, Kim H, Hilsenbeck S, et al: Effect
of epidermal growth factor receptor inhibitor on development of
estrogen receptor-negative mammary tumors. J Natl Cancer Inst.
95:1825–1833. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Li Y, Zhang Y, Hill J, Shen Q, Kim HT, Xu
X, Hilsenbeck SG, Bissonnette RP, Lamph WW and Brown PH: The
Rexinoid LG100268 prevents the development of preinvasive and
invasive estrogen receptor negative tumors in MMTV-erbB2 mice. Clin
Cancer Res. 13:6224–6231. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Russo J: Significance of rat mammary
tumors for human risk assessment. Toxicol Pathol. 43:145–170. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Lari SA and Kuerer HM: Biological markers
in DCIS and risk of breast recurrence: A systematic review. J
Cancer. 2:232–261. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Xiong A, Yang Z, Shen Y, Zhou J and Shen
Q: Transcription factor STAT3 as a novel molecular target for
cancer prevention. Cancers (Basel). 6:926–957. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Yue P and Turkson J: Targeting STAT3 in
cancer: How successful are we? Expert Opin Investig Drugs.
18:45–56. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Zhang X, Yue P, Fletcher S, Zhao W,
Gunning PT and Turkson J: A novel small-molecule disrupts Stat3 SH2
domain-phosphotyrosine interactions and Stat3-dependent tumor
processes. Biochem Pharmacol. 79:1398–1409. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Zhang X, Yue P, Page BD, Li T, Zhao W,
Namanja AT, Paladino D, Zhao J, Chen Y, Gunning PT and Turkson J:
Orally bioavailable small-molecule inhibitor of transcription
factor Stat3 regresses human breast and lung cancer xenografts.
Proc Natl Acad Sci USA. 109:9623–9628. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Zhang X, Sun Y, Pireddu R, Yang H, Urlam
MK, Lawrence HR, Guida WC, Lawrence NJ and Sebti SM: A novel
inhibitor of STAT3 homodimerization selectively suppresses STAT3
activity and malignant transformation. Cancer Res. 73:1922–1933.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Yue P, Lopez-Tapia F, Paladino D, Li Y,
Chen CH, Namanja AT, Hilliard T, Chen Y, Tius MA and Turkson J:
Hydroxamic acid and benzoic acid-based STAT3 inhibitors suppress
human glioma and breast cancer phenotypes in vitro and in vivo.
Cancer Res. 76:652–663. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Deng XS, Wang S, Deng A, Liu B, Edgerton
SM, Lind SE, Wahdan-Alaswad R and Thor AD: Metformin targets Stat3
to inhibit cell growth and induce apoptosis in triple-negative
breast cancers. Cell Cycle. 11:367–376. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Meyskens FL Jr, McLaren CE, Pelot D,
Fujikawa-Brooks S, Carpenter PM, Hawk E, Kelloff G, Lawson MJ,
Kidao J, McCracken J, et al: Difluoromethylornithine plus sulindac
for the prevention of sporadic colorectal adenomas: A randomized
placebo-controlled, double-blind trial. Cancer Prev Res (Phila).
1:32–38. 2008. View Article : Google Scholar : PubMed/NCBI
|
